Cryoport, Inc. (CYRX)
Nasdaq · Industrials · Integrated Freight & Logistics
$18.14+4.07%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $919M
- 52-week range
- $7.61 – $18.24
- 52-week change
- +77.86%
- EPS (trailing)
- −$0.81
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $176M (+12.38%)
- Net income
- $78.3M
- Operating margin
- −20.9%
- Diluted EPS
- $1.40
- Free cash flow
- −$25.0M
From the company’s annual report on SEC EDGAR.
About Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release.
Headquarters: Brentwood, United States · 684 employees · cryoportinc.com